New Drug Combination Shows Promise For African Sleeping Sickness

Main Category: Tropical Diseases
Article Date: 06 Nov 2007 - 17:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

A small clinical trial in Uganda, conducted within a long-established Médecins Sans Frontières (MSF) treatment program for African sleeping sickness, has found that a new combination treatment using the drugs nifurtimox and eflornithine holds promise and deserves further evaluation.

The parasitic disease African sleeping sickness (human African trypanosomiasis, or HAT) threatens millions across remote and conflict-affected regions of sub-Saharan Africa, and causes about 15 000 reported cases every year. Without treatment, HAT progresses from stage 1, infection of the blood and lymph, to stage 2, invasion of the central nervous system, and then to death.

There are few drugs available for treating stage 2. The historical mainstay, melarsoprol, is highly toxic and is ineffective in some areas due to parasite resistance. Eflornithine is the only viable alternative, already established as safe and efficacious, but it is difficult to administer-it is given intravenously and requires 24 hour nursing care, placing an additional workload on the already fragile health systems in HAT-endemic countries.

The new trial, by Gerardo Priotto (Epicentre, Paris, France) and colleagues at MSF and Epicentre, reports on a series of 48 patients treated with a novel combination of nifurtimox (a drug registered for Chagas disease) and eflornithine. Seventeen patients were recruited as part of a terminated randomized trial (previously published in PLoS Clinical Trials, at http://dx.doi.org/10.1371/journal.pctr.0010039), and 31 in a subsequent case series study.

Despite the low sample size, the findings were promising: no cases of treatment failure, no treatment terminations, and no HAT- or treatment-related deaths.

"Nifurtimox plus eflornithine may be the best treatment hope for stage 2 HAT patients in the next decade, while new drugs are developed," say the authors. "A larger, multi-centric trial of the combination is ongoing."

CITATION: Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, et al. (2007) Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series. PLoS Negl Trop Dis 1(2): e64. doi:10.1371/journal.pntd.0000064
Please click here

Disclaimer

This press release refers to an upcoming article in PLoS Neglected Tropical Diseases. The release is provided by journal staff. Any opinions expressed in these releases or articles are the personal views of the journal staff and/or article contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

About PLoS Neglected Tropical Diseases

PLoS Neglected Tropical Diseases is a peer- reviewed, open-access journal devoted to the pathology, epidemiology, prevention, treatment, and control of the neglected tropical diseases, as well as public policy relevant to this group of diseases. All works published in PLoS Neglected Tropical Diseases are open access, which means that everything is immediately and freely available subject only to the condition that the original authorship and source are properly attributed. The Public Library of Science uses the Creative Commons Attribution License, and copyright is retained by the authors.

http://www.plosntds.org/

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource.

Public Library of Science
185 Berry Street, Suite 3100
San Francisco, CA 94107
USA